Janeen Noel Doyle Sells 4,059 Shares of Janux Therapeutics (NASDAQ:JANX) Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) insider Janeen Noel Doyle sold 4,059 shares of the stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $14.03, for a total value of $56,947.77. Following the completion of the sale, the insider owned 75,941 shares of the company’s stock, valued at $1,065,452.23. The trade was a 5.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Janux Therapeutics Stock Down 2.9%

NASDAQ JANX opened at $13.36 on Friday. The company has a market capitalization of $814.69 million, a price-to-earnings ratio of -7.26 and a beta of 2.53. Janux Therapeutics, Inc. has a twelve month low of $12.12 and a twelve month high of $35.34. The stock has a fifty day simple moving average of $14.50 and a 200 day simple moving average of $15.56.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.13. The company had revenue of $3.73 million during the quarter, compared to analyst estimates of $4.36 million. Research analysts expect that Janux Therapeutics, Inc. will post -1.7 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. Truist Financial upgraded Janux Therapeutics to a “strong-buy” rating in a report on Monday, May 4th. UBS Group downgraded Janux Therapeutics from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $57.00 to $15.00 in a report on Wednesday, April 15th. Guggenheim decreased their price target on Janux Therapeutics from $68.00 to $58.00 and set a “buy” rating for the company in a report on Friday, May 8th. Wall Street Zen upgraded Janux Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, April 5th. Finally, Barclays downgraded Janux Therapeutics from an “overweight” rating to an “underweight” rating and decreased their price target for the stock from $29.00 to $14.00 in a report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Janux Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $45.85.

Hedge Funds Weigh In On Janux Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Bank of America Corp DE boosted its holdings in shares of Janux Therapeutics by 8.6% during the 1st quarter. Bank of America Corp DE now owns 801,646 shares of the company’s stock worth $11,143,000 after buying an additional 63,316 shares in the last quarter. Irenic Capital Management LP bought a new position in shares of Janux Therapeutics during the 1st quarter worth approximately $10,645,000. ADAR1 Capital Management LLC boosted its holdings in shares of Janux Therapeutics by 21.6% during the 1st quarter. ADAR1 Capital Management LLC now owns 298,546 shares of the company’s stock worth $4,150,000 after buying an additional 53,094 shares in the last quarter. Rock Springs Capital Management LP grew its stake in shares of Janux Therapeutics by 2.3% in the 1st quarter. Rock Springs Capital Management LP now owns 367,009 shares of the company’s stock valued at $5,101,000 after buying an additional 8,211 shares during the period. Finally, Quantinno Capital Management LP grew its stake in shares of Janux Therapeutics by 7.6% in the 1st quarter. Quantinno Capital Management LP now owns 26,064 shares of the company’s stock valued at $362,000 after buying an additional 1,846 shares during the period. 75.39% of the stock is currently owned by institutional investors.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.